About 32 results found for searched term "MD2-IN-1" (0.092 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5105 | MD2-TLR4-IN-1 | TLR |
| MD2-TLR4-IN-1 is an inhibitor of myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex, inhibiting lipopolysaccharides (LPS)-induced expression of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) in macrophages with IC50 values of 0.89 μM and 0.53 μM, respectively. | ||
| M20588 | MD2-IN-1 | TLR |
| MD2-IN-1 is an inhibitor of Myeloid differentiation protein 2 (MD2) with a KD value of 189 μM. | ||
| M43085 | MDM2/XIAP-IN-1 | Others |
| MDM2/XIAP-IN-1 is an orally active inhibitor of dual MDM2/XIAP. | ||
| M55898 | MDM2-IN-1 | p53 |
| MDM2-IN-1 is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration. | ||
| M2042 | Cilengitide | Integrin |
| EMD 121974, NSC 707544 | ||
| Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively. | ||
| M2207 | NSC 66811 | Mdm2 |
| NSC 66811 is a potent MDM2 inhibitor with Ki value of 120 nM, which disrupts MDM2-p53 interaction and activates p53 function. | ||
| M2381 | AMD3465 hexahydrobromide (AMD3465 ) | CXCR |
| GENZ-644494 hexahydrobromide | ||
| AMD3465 hexahydrobromide（AMD3465 ) is an effective CXCR4 antagonist that inhibits 12G5 mAb in SupT1 cells. The IC50 values of CXCL12AF647 and CXCR4 were 0.75 nM and 18 nM, respectively. AMD 3465 also effectively inhibited X4 HIV replication (IC50, 1-10 nM), but not R5 HIV replication. | ||
| M2403 | MDK83190 | Caspase |
| Apoptosis Activator 2; MDK-83190 | ||
| MDK83190 (Apoptosis Activator 2) strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells. | ||
| M2578 | RITA | p53 |
| NSC 652287 | ||
| RITA (NSC 652287) is a MDM2 inhibitor and DNA damage agent for A498 (wild type) and TK-10 (mutation) cell lines with a GI50 of 17 nM and 32 nM, respectively. | ||
| M2584 | MDL-29951 | GluR |
| MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo with IC50 value of 0.14 mM ([3H]glycine binding). | ||
| M2895 | Nutlin-3b | Mdm2 |
| (+)-Nutlin-3 | ||
| Nutlin-3b is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite enantiomer Nutlin-3a. | ||
| M2961 | Procaine hydrochloride | Sodium Channel |
| Novocaine HCl | ||
| Procaine is an inhibitor of sodium channel, NMDA receptor and nAChR with IC50 of 60 μM, 0.296 mM and 45.5 μM, which is also an inhibitor of 5-HT3 with KD of 1.7 μM. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M3014 | SL-01 | Mdm2 |
| SL-01 is a p53-Mdm2 interaction inhibitor with IC50 of 3.18 μM. | ||
| M4460 | Oroxylin-A | CDK |
| Baicalein 6-methyl ether; 6-Methoxybaicalein | ||
| Oroxylin A is an active flavonoid that inhibits the phosphorylation of MDM2 and SIRT1 through the inhibition of CDK9, thus inhibiting MDM2-mediated degradation of P53 and SIRT1-mediated deacetylation of P53, and ultimately stabilizing the P53 protein.Oroxylin A has strong anticancer activity. | ||
| M4833 | Eliprodil | GluR |
| SL-820715 | ||
| Eliprodil is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM). | ||
| M5280 | XMD8-87 | Tyrosinase |
| ACK1-B19 | ||
| XMD8-87 is a novel tyrosine kinase nonreceptor 2(TNK2) inhibitor with IC50s of 38 nmol/L and 113 nmol/L for the D163E and R806Q mutations. | ||
| M5281 | XMD16-5 | Tyrosinase |
| XMD16-5 is a novel tyrosine kinase nonreceptor 2(TNK2) inhibitor with IC50s of 16 nmol/L and 77 nmol/L for the D163E and R806Q mutations. | ||
| M6217 | Mavorixafor | CXCR |
| AMD-070; AMD-11070 | ||
| Mavorixafor (AMD-070) is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. | ||
| M6621 | Conantokin-R | Others |
| Con-R | ||
| Conantokin-R is a potent, non-competitive NMDA receptor peptide antagonist with an IC50 of 93 nM.Conantokin-R is also NR2 subunit selective. It inhibits the inward current induced by NMDA in CNS neurons (IC50 = 350 nM). In addition, Conantokin R bound to Zn2+ and Mg2+ with Kd of 0.15 μM and 6.5 μM, respectively. | ||
| M7535 | HDM201 | Mdm2 |
| NVP-HDM201; Siremadlin | ||
| HDM201 is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4. | ||
| M7934 | MDL 28170 | Gamma-secretase/Beta-secretase |
| Calpain Inhibitor III | ||
| Mdl-28170 (Calpain Inhibitor III) is a potent, selective, membrane-permeable Inhibitor of cysteine protease (Calpain Inhibitor III) that can quickly cross the blood-brain barrier after systemic administration. Mdl-28170 also blocks gamma-secretase. | ||
| M10374 | AMG 232 | Mdm2 |
| Navtemadlin ; KRT-232 | ||
| AMG 232 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg). *The compound is unstable in solutions, freshly prepared is recommended | ||
| M10781 | Alrizomadlin | Mdm2 |
| APG-115; AA-115 | ||
| Alrizomadlin (APG-115) is an oral active small molecule MDM2 protein inhibitor that binds to MDM2 protein.IC50 value and Ki The values are 3.8 nM and 1 nM, respectively. Alrizomadlin blocks MDM2 interaction with p53 and induces cell cycle arrest and apoptosis in a p53-dependent manner. | ||
| M13393 | NVP-CGM097 | Mdm2 |
| CGM097 | ||
| NVP-CGM097 is a highly effective and selective MDM2 inhibitor with a Ki value of 1.3 nM. | ||
| M13569 | S29434 | Autophagy |
| NMDPEF | ||
| S29434 (NMDPEF) is a potent, competitive, selective and cell-permeable inhibitor of quinone reductase 2 (QR2), with IC50s ranging from 5 to 16 nM for human QR2 at different organizational levels, and has good selectivity for QR2 over QR1. | ||
| M13592 | ENMD-2076 Tartrate | Aurora Kinase |
| ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. | ||
| M13939 | Mavorixafor trihydrochloride | CXCR |
| AMD-070 trihydrochloride | ||
| Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. | ||
| M14148 | STAT3-IN-1 | STAT |
| STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis. | ||
| M24774 | MDX-1342 | Others |
| MDX-1342 is a fully human monoclonal antibody (HuMAb) of targeting CD19-membrane receptor. MDX-1342 can specifically bind to human CD19 antigen with high affinity and has antibody-dependent cellular cytotoxicity (ADCC) effect. MDX-1342 can be used for the research of B-lymphocyte malignancies and autoimmune. | ||
| M25131 | Imdevimab | Anti-infection |
| REGN10987 | ||
| Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab , it reduces viral load and improves diseases. | ||
| M28049 | SP-141 | p53 |
| SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells. | ||
| M28357 | MI-1061 | p53 |
| MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
